A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This open-label study will assess the pharmacodynamics, safety and efficacy of RO5083945 as
compared to cetuximab in patients with head and neck squamous cell carcinoma. Patients will
receive at least 2 infusions of either RO5083945 or cetuximab. Anticipated time on study
treatment is up to 3 months, and target sample size is <50.